Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KINE-201C
- Development stage
- Preclinical
- Lead developer
- Kine Sciences
- Modality
- Peptides
01
Overview
KINE-201C is an investigational peptide therapeutic being developed by Kine Science for the treatment of Chronic Obstructive Pulmonary Disease (COPD). As part of Kine Science's pipeline of 'Kine-Peptides,' KINE-201C is designed to modulate the activity of Th2 (Type 2 helper T) cells. Th2 cells are key drivers of the inflammatory and allergic responses that contribute to the pathophysiology of chronic respiratory diseases. By modulating these cells, KINE-201C aims to reduce airway inflammation and improve lung function in patients with COPD. The drug is currently in the discovery or early preclinical stage, and while its specific molecular target remains undisclosed, its mechanism focuses on restoring immune homeostasis by dampening Th2-mediated pathways.
02
Targets
TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on KINE-201C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KINE-201C.